Navigation Links
Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
Date:10/19/2008

TR-701 Phase 1 Clinical Trial Results Disclosed

SAN DIEGO, Oct. 20 /PRNewswire/ -- Trius Therapeutics, Inc., a biopharmaceutical company developing "Best-in-Class" drugs for the treatment of serious bacterial infections, announced today that the results of multiple studies on its lead program, TR-701, and its other pipeline programs will be presented in eighteen presentations at the upcoming joint Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and Infectious Diseases Society of America (IDSA) meeting in Washington, DC. Thirteen of the presentations focus on TR-701, a second generation oxazolidinone that recently commenced Phase 2 clinical studies.

"Acceptance of these presentations by the ICAAC committee highlights the interest in and value of the TR-701 program, the Trius pipeline, and our underlying technologies," stated Jeffrey Stein, Ph.D., President and CEO of Trius Therapeutics. "We are especially pleased to provide details of our TR-701 Phase 1 clinical trial results that support the once-daily dosing and short course of therapy in our recently initiated Phase 2 study in complicated skin and skin structure infections (cSSSIs). It is also exciting to see that the results of studies by external investigators demonstrate the drug's increased potency and expanded spectrum of activity."

The presentations are as follows:

Saturday, October 25th

(Poster Summary Session, Ballroom A/B, 10:00 am - 12:00 pm)

-- Oral Presentation: Overview of TR-701 and TR-700 Posters and

Presentations

(Poster Session 23, 12:15 pm - 1:15 pm)

-- F1-334: Discovery and SAR of a Novel Series of Pyrimidine Antibacterials

Targeting Methionyl-tRNA Synthase (MetRS)

-- F1-335: In Vitro Activity of Rx100472 Against Clinically Important

Bacteria

-- F1-336: Advanced Microbiology Study of Rx100472, A Novel Methionyl-tRNA

Synthetase (MetRS) inhibi
'/>"/>

SOURCE Trius Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
2. PacificGMP Completes GMP Product Fill for Trius Therapeutics
3. Trius Doses First Patient in Antibacterial Phase 2 Trial
4. For Most, Good Oral Care Does More Than Antibiotics to Prevent Dental-Related Heart Problems, Reports the Harvard Heart Letter
5. ActivBiotics Proposes Development Strategy for Its Novel Rifamycin Antibiotics
6. Bad News to Bad Bugs: Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity
7. SuperGens Novel Hypomethylating Agent Highlighted at AACR Plenary Session
8. International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
9. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
10. Blood Spot Technology at ZRT Highlighted in March Issue of Journal of Diabetes Science & Technology - A Convenient Alternative to Serum Testing for Health Screening
11. ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... HARRISBURG, Pa. , Jan. 14, 2014 Dynamic Healthcare ... ("GMH"), announced today that it acquired Progressive Home Medical Equipment, ... January 7, 2014. The terms of the acquisition were not ... medical equipment ("DME") company providing a wide range of sleep, ...
(Date:1/14/2014)... 14, 2014 Animal Emergency Critical Care, a LifeCentre partner practice, ... is the first in Loudoun County ... Dr. Susan M. Barnes , Medical Director, is a ... Dr. Cole Taylor , are avid scuba divers. "As altitude ...
(Date:1/14/2014)... 2014 NineSigma , Inc., the leading innovation ... Leadership Summit , May 14-16, 2014 at the Global ... . This is the premier ... breakthrough achievements through open innovation. Participants will learn how ...
Breaking Medicine Technology:Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... than doubled time without tumor growth and reduced the ... with placebo- Only once-daily oral cancer treatment to directly ... tumor cell division and blood vessel growth- Phase III ... additional cancersEAST HANOVER, N.J., March 30 Novartis announced ...
... Laboratory Response Network (LRN), the national laboratory system charged ... its first decade at its national meeting in Orlando, ... of Public Health Laboratories (APHL), the Centers for Disease ... Investigation (FBI) to test for agents of bioterrorism, the ...
Cached Medicine Technology:Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib 2Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib 3Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib 4Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib 5Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib 6Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib 7Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib 8Nation's Laboratory Response Network Marks First Decade of Protecting Public Health 2
(Date:7/9/2014)... retrospective study conducted by researchers at Tufts University School ... with intellectual and developmental disabilities, the likelihood of having ... care increased. The findings, published in the July/August issue ... improve interventions designed to address the oral health of ... the dental records of 107 patients at one of ...
(Date:7/9/2014)... age with kidney and heart disease have raised concerns ... adults. However, in the first study to look closely ... Medicine at the University of Pennsylvania report that older ... expectancy and cardiovascular health as very healthy older people ... the ever increasing organ transplant waitlists, the authors of ...
(Date:7/9/2014)... A study published in the scientific journal Nature ... two researchers at Universit Laval, reveals that it is ... that involves rekindling pain so that it can subsequently ... to alleviate chronic pain. , The researchers from the ... en sant mentale de Qubec (IUSMQ) were inspired by ...
(Date:7/9/2014)... the Keck School of Medicine of the University ... lacking a specific component of the immune system ... complication of infection. The discovery suggests that blocking ... in human autoimmune and hyper-inflammatory diseases such as ... study was published online on June 23 in ...
(Date:7/8/2014)... Program in Memory Restoration has been awarded up to ... (DARPA) for a four -year project aiming to help ... of experts in neurosurgery, engineering, neurobiology, psychology and physics ... memory prosthesis in the brain. , Memory is the ... brain encode information, store it and retrieve it. Certain ...
Breaking Medicine News(10 mins):Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:Penn study finds living kidney donation does not increase risk of death or heart disease for older 2Health News:Discovery of a new means to erase pain 2Health News:DARPA awards UCLA $15 million to restore lost memory 2Health News:DARPA awards UCLA $15 million to restore lost memory 3
... of Trade Alerts on stocks making news today.Investors can view ... http://www.BeaconEquity.com/m Today,s Trade Alerts include: Humana Inc. (NYSE: ... Aetna Inc. (NYSE: AET ), CIGNA Corp. (NYSE: ... UNH ) and Universal American Corp. (NYSE: UAM ...
... , Improving rural sanitation by 65 percent could save ... scientists in Pennsylvania conclude in a new study on ... ACS, semi-monthly journal Environmental Science & Technology , ... experience the greatest savings in life. , In the ...
... CHICAGO, March 9 Illinois was the first state in ... station, police station and emergency medical facility that is required ... Abandoned Newborn Infant Protection Act to post a uniform sign ... informing persons that a newborn infant may be relinquished at ...
... FORT WORTH, Texas, March 9 Galderma Laboratories ... and Cetaphil(R) DailyAdvance(TM) Ultra Hydrating Lotion, have been ... Acceptance.The Seal of Acceptance criteria include review of ... well as ingredient and formulation data.The NEA Seal ...
... FoundationCHICAGO, March 9 Dental patients who have ... about how osteoporosis medications might affect their oral ... separate fact from fiction. The American Dental Association ... create the brochure, "Osteoporosis Medications and Your Dental ...
... Italian researchers report bedridden patients walked 24 hours after ... "bone cement" into lesions in patients whose cancer has ... to rise from their deathbeds and live the remainder ... presenting these findings Monday at the Society of Interventional ...
Cached Medicine News:Health News:Beacon Equity Issues Technical Trade Alerts on Healthcare Plan Stocks: HUM, WLP, AET, CI, UNH, UAM 2Health News:American Chemical Society's Weekly PressPac -- March 4, 2009 2Health News:American Chemical Society's Weekly PressPac -- March 4, 2009 3Health News:American Chemical Society's Weekly PressPac -- March 4, 2009 4Health News:American Chemical Society's Weekly PressPac -- March 4, 2009 5Health News:American Chemical Society's Weekly PressPac -- March 4, 2009 6Health News:American Chemical Society's Weekly PressPac -- March 4, 2009 7Health News:American Chemical Society's Weekly PressPac -- March 4, 2009 8Health News:American Chemical Society's Weekly PressPac -- March 4, 2009 9Health News:Save Abandoned Babies Foundation Commends Illinois Hospitals for Being 100% in Compliance in Displaying 'Safe Haven Signs' 2Health News:Three Cetaphil(R) Products Awarded National Eczema Association Seal of Acceptance 2Health News:ADA Informs Patients About Osteoporosis Medications and Oral Health 2Health News:ADA Informs Patients About Osteoporosis Medications and Oral Health 3Health News:Bone Cement Eases Pain of Late-Stage Cancers 2Health News:Bone Cement Eases Pain of Late-Stage Cancers 3
Toxoplasma IgM II ELISA....
HSV 1 & HSV 2 DFA Test....
Herpes Simplex Virus 2 IgG ELISA....
Herpes Simplex Virus 1 IgG ELISA....
Medicine Products: